Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.095
Buy
RSI(14)
51.816
Neutral
STOCH(KDJ)(9,3,3)
46.967
Neutral
ATR(14)
0.377
High Vlolatility
CCI(14)
24.758
Neutral
Williams %R
57.600
Sell
TRIX(12,20)
0.481
Sell
StochRSI(14)
0.000
Sell
Search
Can Fite Biopharma Ltd
CANFAdd to Watchlist
3.360USD
-0.130-3.72%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
7.63MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Can Fite Biopharma Ltd
Currency: USD Updated: 2026-05-15Key Insights
Can Fite Biopharma Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 101 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Can Fite Biopharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Can Fite Biopharma Ltd Highlights
StrengthsRisks
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Growing
The company is in a growing phase, with the latest annual income totaling USD 405.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 405.00K.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.13K shares, decreasing 71.76% quarter-over-quarter.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
50.000
Target Price
+1332.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Can Fite Biopharma Ltd is 5.51, ranking 150 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 155.00K, representing a year-over-year decrease of 21.32%, while its net profit experienced a year-over-year decrease of 45.28%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
4.00
Operational Efficiency
4.00
Growth Potential
4.55
Shareholder Returns
5.00
Can Fite Biopharma Ltd's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Can Fite Biopharma Ltd is 7.35, ranking 76 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -0.00, which is -226773.68% below the recent high of 4.31 and -32002015.79% above the recent low of -608.04.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 101/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Can Fite Biopharma Ltd is 7.00, ranking 119 out of 155 in the Pharmaceuticals industry. The average price target is 4.50, with a high of 11.00 and a low of 2.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
50.000
Target Price
+1332.66%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Can Fite Biopharma Ltd
CANF
2
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Can Fite Biopharma Ltd is 7.41, ranking 40 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.02 and the support level at 2.77, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.448
Sell
MA10
3.446
Sell
MA20
3.205
Buy
MA50
3.277
Buy
MA100
3.814
Sell
MA200
4.412
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Can Fite Biopharma Ltd. The Pharmaceuticals industry's average is 5.23. The company's beta value is 1.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.11
VaR
+6.67%
240-Day Maximum Drawdown
+74.39%
240-Day Volatility
+331.74%
Return
Best Daily Return
60 days
+20.40%
120 days
+1855.84%
5 years
+1855.84%
Worst Daily Return
60 days
-23.59%
120 days
-25.03%
5 years
-32.09%
Sharpe Ratio
60 days
-0.65
120 days
+1.41
5 years
+0.38
Risk Assessment
Maximum Drawdown
240 days
+74.39%
3 years
+93.51%
5 years
+98.64%
Return-to-Drawdown Ratio
240 days
+2.78
3 years
+0.02
5 years
-0.17
Skewness
240 days
+15.48
3 years
+26.65
5 years
+34.19
Volatility
Realised Volatility
240 days
+331.74%
5 years
+174.88%
Standardised True Range
240 days
+6.75%
5 years
+10.99%
Downside Risk-Adjusted Return
120 days
+5051.81%
240 days
+5051.81%
Maximum Daily Upside Volatility
60 days
+233.41%
Maximum Daily Downside Volatility
60 days
+70.91%
Liquidity
Average Turnover Rate
60 days
+0.03%
120 days
+0.07%
5 years
--
Turnover Deviation
20 days
-23.19%
60 days
-36.33%
120 days
+33.88%
Peer Comparison
Pharmaceuticals
Can Fite Biopharma Ltd
CANF
5.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
